Synthetic Biology Funding Tracker (241 deals)

Our funding tracker covering the synthetic biology market

Below is the table listing all the deals. You may find our methodology at the end of this page.

And, if you want to gain a deeper understanding of the market and its current dynamics, get our report covering the Synthetic Biology Market.

Is synthetic biology actually well funded right now?

Synthetic biology is well funded today, but the typical startup sees a much smaller market than the billion-dollar headline suggests.

We tracked 241 private financings across 219 companies and at least $4.208 billion of quantifiable capital. The median disclosed round was $12.55 million, compared with an average of $22.62 million.

That gap already tells us a lot. A $12 million financing is normal here. A $100 million financing is a different class of event.

The market also has a disclosure problem. Only 186 of the 241 rounds have amounts clean enough to aggregate after audit. A large share of the missing amounts comes from China, where announcements often say only "tens of millions of RMB." So $4.208 billion should be read as a conservative amount we can actually quantify, rather than the exact amount raised by every company in the market.

For a founder or investor looking at synthetic biology now, the useful picture is a broad venture market with plenty of real funding, plus a much narrower group of companies able to raise very large checks.

Does the $4.2 billion headline make synthetic biology funding look healthier than it is?

Yes. The $4.2 billion synthetic biology funding total looks much more evenly distributed than the underlying market really is.

Only 23 rounds were above $50 million. They represent 9.5% of all financings but 49.6% of the capital we could quantify.

Seven rounds were above $100 million and generated almost one-quarter of measured funding on their own.

The interesting part is that no single deal completely hijacks the dataset. Encoded Therapeutics' $275 million financing is the largest, yet it accounts for only 6.5% of quantifiable capital. The concentration comes from a whole upper tier of $50 million, $100 million and $150 million-plus financings.

From the outside, that can make the market look more evenly funded than it is. There are hundreds of funded companies, while roughly half the money sits in fewer than one deal in ten.

Is synthetic biology funding really spread across hundreds of companies?

Yes, synthetic biology funding is genuinely spread across a large number of companies, although serious scale capital is much harder to reach.

We found 219 companies in the market. Of those, 199 appear only once during the full financing window, 18 appear twice and just two appear three or more times.

So 90.9% of companies have only one observed financing in the period.

That makes the market quite different from one where five established winners repeatedly absorb most new capital. Companies with a single qualifying round account for roughly $3.56 billion, compared with about $651 million for companies that appear more than once.

The top of the market is still meaningful. Encoded Therapeutics raised $275 million, Strand Therapeutics $153 million, Outpace Bio $144 million and EvolutionaryScale more than $142 million. Yet even the ten largest companies together account for only about 31% of quantifiable capital.

Synthetic biology currently has plenty of funded companies. What it has far less of is companies repeatedly coming back for another major round.

Company	Capital raised in the period	Qualifying rounds
Encoded Therapeutics	$275M	1
Strand Therapeutics	$153M	1
Outpace Bio	$144M	1
EvolutionaryScale	>$142M	1
BrainChild Bio	$116M	1
Profluent	$106M	1
Tropic	$105M	1
Trogenix	$95M	1
Epicrispr Biotechnologies	$90M	1
MicroCyto	$86.4M+	3

What does a normal synthetic biology startup raise these days?

A normal synthetic biology startup is usually raising somewhere in the single-digit to low-double-digit millions, rather than the $50 million-plus amounts that dominate funding headlines.

Among rounds where we could establish a usable amount, 46 were below $5 million and another 82 were between $5 million and $20 million. Together, those two groups make up almost 69% of quantified financings.

Only 24 quantified rounds reached $50 million or more.

Stage changes the answer quickly. The median Seed round was $4.6 million. Series A moved up to $15.5 million, Series B to $40.9 million and Series C to $53 million.

So if someone asks what synthetic biology companies "normally raise," $10 million to $15 million is much closer to reality than $50 million.

The large rounds become common only after a company has crossed into a much smaller group where clinical development, manufacturing, infrastructure or commercial rollout can justify a completely different capital requirement.

Which parts of synthetic biology are getting the serious money right now?

Synthetic biology therapeutics gets the most money by a wide margin, while biofoundries and engineered microbes produce more deals without attracting the same size of checks.

Therapeutics generated $1.526 billion from 43 financings. That is 36.3% of quantifiable capital from only 17.8% of the deals.

Biofoundries show almost the reverse pattern. They lead the market with 52 financings but generated $561.8 million, with a median round of only $8.8 million.

AI-heavy design software is another interesting case. Just 21 financings produced $582.5 million, giving the category one of the highest capital levels per deal in the market.

Food platforms sit somewhere in between. Their $608.5 million of measured funding comes from 36 deals and includes some genuinely large commercial-scale rounds, most notably Tropic's $105 million financing.

The useful distinction today is between categories where investors are mostly paying for technical progress and categories where the next milestone itself can cost tens of millions of dollars.

Category	Deals	Companies	Quantifiable capital	Median round
Synthetic Biology Therapeutics	43	42	$1.526B	$14.0M
Synbio Food Platforms	36	32	$608.5M	$12.3M
Synbio Design Software	21	18	$582.5M	$21.0M
Biofoundry Platforms	52	48	$561.8M	$8.8M
Engineered Microbes	48	43	$550.0M	$11.1M
Synbio Materials Platforms	41	37	$379.3M	$13.9M
Total	241	219	$4.208B+	$12.55M

Why are synthetic biology therapeutics getting such huge checks?

Synthetic biology therapeutics gets bigger checks because these companies are now paying for clinical trials, regulatory work and manufacturing on top of the original science.

The recent deals make that especially clear.

Encoded Therapeutics raised $275 million after its ETX101 program had reached pivotal development. The company said the financing would support pivotal and expansion studies as well as commercial-scale expansion of its internal GMP manufacturing capability.

BrainChild Bio raised $116 million as its lead CAR-T program moved into a pivotal trial for pediatric brain cancer. Trogenix raised $95 million to move its genetic-medicine programs for aggressive cancers into clinical development. Outpace Bio's $144 million Series B was raised to push programmed T-cell therapies toward clinical proof of concept.

These checks are large because the work has become expensive.

Current FDA requirements illustrate the progression. Drug developers moving into human studies need clinical protocols, toxicology data and manufacturing information, while later trials generally involve larger patient populations and more developed manufacturing controls.

That is why therapeutics can take such a disproportionate share of synthetic biology funding without requiring hundreds of companies. A relatively small number of clinical programs can consume a great deal of capital very quickly.

Is AI-driven biology becoming a major synthetic biology funding market?

Yes, AI-driven biology is already attracting unusually large amounts of synthetic biology capital, even though the category still has relatively few companies.

Synbio Design Software contains only 21 deals across 18 companies, but we measured $582.5 million of funding. The median round is $21 million, higher than in any of the other main categories.

EvolutionaryScale launched with more than $142 million of Seed funding while developing ESM3, a large generative model for protein sequence, structure and function. That is an extraordinary amount of capital for a company at Seed.

Profluent later raised $106 million to expand its AI protein-design work across genome editors, antibodies, enzymes and other biological systems.

These deals show why the normal relationship between company age and round size gets messy in AI biology. A frontier biological model can require expensive compute, very large datasets and highly specialized scientific teams before the company has followed a traditional biotech financing ladder.

There is still concentration here. EvolutionaryScale alone represents roughly one-quarter of measured design-software capital.

Even with that caveat, investors are clearly willing these days to fund a small number of AI-native biology platforms at a scale much closer to advanced biotech than conventional scientific software.

Why do biofoundries and engineered-microbe startups raise so much less?

Biofoundry and engineered-microbe companies are getting funded often, but very few have reached the point where investors are writing genuinely large scale-up checks.

Biofoundry Platforms produced 52 financings, the highest deal count of any category. Only five are later-stage rounds.

Engineered Microbes produced 48 financings, including 32 Seed or Series A deals, but again only five later-stage or Growth rounds.

The problem starts to make sense once these businesses move beyond the lab.

A 2026 Nature Communications review of industrial biomanufacturing highlights exactly the kinds of issues that appear at scale: reactor design, oxygen and mass transfer, downstream processing, yield, feedstocks and the economics of large production systems.

Those problems can turn a technically successful fermentation process into a difficult industrial business.

Food biotechnology faces a similar challenge. A recent Nature Food analysis points to fermentation infrastructure, purification costs, feedstock volatility and limited infrastructure financing as major constraints for precision-fermentation products.

So these categories currently have plenty of experimentation and early validation. The thinner part of the market begins when the company has to prove that the biology works economically at industrial scale.

Where does synthetic biology funding get really hard?

Synthetic biology funding gets much harder after Series A.

We counted 82 Seed rounds and 75 Series A rounds, so the early funding ladder is relatively full. Series B falls to only 19 deals.

At the same time, the typical check rises sharply. The median moves from $15.5 million at Series A to $40.9 million at Series B.

The companies are older by then as well. Median age moves from two years at Seed to four at Series A and six at Series B. Series C companies have a median age of ten years.

That combination gives us a fairly intuitive picture of where the market starts demanding much more. A company may spend its first few years proving that its biology works. The next round often has to fund a much more expensive question: can the company turn that biology into a product, clinical program or industrial process that works at scale?

The Series A-to-B gap does not give us a literal company survival rate because the dataset covers a fixed financing window rather than following one startup cohort from birth to exit.

Still, a fall from 75 Series A financings to 19 Series B financings is far too large to dismiss as noise. This is currently the clearest bottleneck in the funding ladder.

Stage	Deals	Median round	Median company age
Seed	82	$4.6M	2 years
Series A	75	$15.5M	4 years
Series B	19	$40.9M	6 years
Series C	10	$53.0M	10 years
Series D+	3	$165M*	11 years
Growth Equity	3	$35.2M	10 years
Unknown stage	49	$11.5M	4 years

Is synthetic biology funding mostly going to new startups or companies investors already know?

Synthetic biology funding is mostly going to companies that have already raised before.

We classified 185 financings as follow-ons, compared with 55 first financings and one case where the status could not be established confidently.

Follow-ons therefore represent 76.8% of deals and more than 90% of the capital we could quantify.

The check sizes are different too. A first financing has a median of roughly $4.2 million, while a follow-on has a median of about $14 million.

That tells us more than simply saying the market has lots of young companies. Investors are still backing new entrants, but the largest pool of money today goes toward companies that have already cleared at least one financing hurdle.

About one-quarter of the 219 companies in the market appear to be receiving their first outside financing.

For founders, the progression is pretty clear: getting into the market is possible with a relatively modest round; keeping enough investor confidence to finance the next several years is the harder part.

Do corporate investors actually matter in synthetic biology?

Yes, corporate investors matter quite a lot in synthetic biology, especially in businesses where manufacturing, customers and market access are part of the technology problem.

We found an identifiable strategic investor in 58 financings, equal to 24.1% of all deals.

Rounds with strategic participation had a median size of $15 million, compared with $11 million when no strategic investor was present.

Materials had 17 strategic-backed rounds and food had 14, the two highest counts in the market.

Samsara Eco is a good example of why. Its roughly $65 million US-equivalent financing included lululemon, and that relationship later developed into a 10-year offtake plan covering recycled nylon and polyester. The commercial commitment could ultimately supply a meaningful share of lululemon's fiber needs.

Tropic offers another version. Corteva co-led its $105 million Series C as the company moved into larger-scale production and global commercialization of gene-edited crops. Corteva describes its Catalyst platform as combining investment with development, commercialization and route-to-market capabilities.

For industrial synthetic biology, that kind of investor can bring something a venture fund cannot: a future customer, a supply-chain partner or a route into an existing market.

Which investors keep coming back to synthetic biology?

No small group of venture firms currently controls synthetic biology funding; the lead-investor base is unusually fragmented.

We were able to identify a lead or co-lead in 188 financings and found 234 distinct lead-investor names.

Only 20 of those investors appear as a lead more than once.

Main Sequence and RA Capital Management lead or co-lead three deals each. GV, Janus Henderson, Sofinnova Partners, Radical Ventures, Alven and several others appear twice.

That fits the structure of the market. A company developing cancer gene therapy needs a different investor skill set from a fermentation company or an AI protein-design platform.

The result is a market funded by many specialist pockets rather than one dominant synthetic-biology VC club.

Lead investor	Deals led or co-led	Combined size of those rounds
Main Sequence	3	$70.4M
RA Capital Management	3	$207M
GV	2	$318M
Janus Henderson Investors	2	$145M
M&G Investments	2	$80M
Sofinnova Partners	2	$78M
Radical Ventures	2	$66M
Alven	2	$53M
Crédit Mutuel Innovation	2	$46.5M
Daphni	2	$31.1M

Where is synthetic biology funding actually happening right now?

Synthetic biology funding is geographically split: Asia-Pacific produces the most deals, while North America attracts the biggest pool of disclosed money.

Asia-Pacific accounts for 96 financings, against 69 in North America and 69 in Europe.

China alone contributes 78 deals, more than any other country. The United States follows with 65, then the United Kingdom with 24.

The dollar picture looks very different. North America accounts for $2.067 billion of quantifiable capital, almost half the measured market. Europe reaches $1.358 billion and Asia-Pacific $702.8 million.

We should be more confident in the deal-count comparison than the exact capital gap. Many Chinese financings do not disclose a precise size, which pulls down the measurable Asia-Pacific total.

Still, the basic pattern is hard to miss. China has a very large population of funded synthetic biology companies, while the United States produces many more of the giant disclosed checks at the top of the market.

Is synthetic biology funding steady these days, or does it still come in bursts?

Synthetic biology funding is fairly steady by number of deals, while the amount of money invested can change dramatically from one month to the next.

Across the 32 completed months in our measurement period, the market averaged 7.4 deals a month and had a median of seven.

The busiest completed month had 14 deals, only twice the median. There was funding activity throughout the period rather than long stretches where the market simply stopped.

Money behaves differently. The average completed month produced about $117 million of quantifiable capital, while the median was $93.9 million. The strongest completed month reached $338.5 million.

The latest activity shows how quickly that can move. A handful of recent financings produced hundreds of millions of dollars, led by Encoded Therapeutics at $275 million and BrainChild Bio at $116 million.

Those months can look like a sudden market boom even when the number of companies raising is fairly normal.

When synthetic biology funding appears to spike, the first thing to check is the size of the largest two or three deals before concluding that financing conditions changed for everybody.

What is synthetic biology funding still missing today?

Synthetic biology still lacks a deep population of later-stage companies.

There are 157 Seed and Series A financings in the market, compared with only 19 Series B, ten Series C, three Series D+ and three Growth Equity deals.

No category has dozens of companies raising repeatedly at mature stages.

Food comes closest to building a visible later-stage group, with nine later-stage financings. Therapeutics has seven. Biofoundries, engineered microbes and materials each have five.

The absence is especially striking in biofoundries. That category has more deals than any other part of the market, yet very few companies have reached later-stage financing.

As we saw previously, the funding ladder becomes much narrower once checks have to move into the $40 million-plus range.

That is the unresolved question in synthetic biology today. The market has already shown that it can create and fund hundreds of technically ambitious startups. We still do not know how many of them can become large, repeatably financed businesses.

What should we actually take away from synthetic biology funding right now?

Synthetic biology funding today looks like a broad startup market sitting on top of a much narrower scale-capital market.

Hundreds of companies can get financed, and the normal round is still in the low tens of millions. The very large dollar totals come from a much smaller layer of companies that have reached expensive clinical, computational, manufacturing or commercial milestones.

Therapeutics currently has the clearest path to very large checks because clinical development and GMP manufacturing can consume huge amounts of capital. AI-driven biological design is also attracting unusually large rounds much earlier in the company lifecycle.

Industrial biology has a different problem. Biofoundries, engineered microbes, food and materials companies can attract plenty of early financing, but scaling fermentation, purification, production and distribution is where economics start getting much harder.

Corporate investors are particularly relevant in those industrial categories because they can bring manufacturing capacity, customers, offtake and market access alongside capital.

The biggest weakness in the market remains the transition beyond Series A. Early funding is abundant enough to create a large startup population; far fewer companies are currently convincing investors to finance the next stage at $40 million, $50 million or more.

That is probably the cleanest way to read synthetic biology funding as of now: the market has no shortage of promising science. The real scarcity begins when that science has to become a scalable company.